Literature DB >> 26430783

Patterns of Emphysema Heterogeneity.

Arschang Valipour1, Pallav L Shah, Wolfgang Gesierich, Ralf Eberhardt, Greg Snell, Charlie Strange, Robert Barry, Avina Gupta, Erik Henne, Sourish Bandyopadhyay, Philippe Raffy, Youbing Yin, Juerg Tschirren, Felix J F Herth.   

Abstract

BACKGROUND: Although lobar patterns of emphysema heterogeneity are indicative of optimal target sites for lung volume reduction (LVR) strategies, the presence of segmental, or sublobar, heterogeneity is often underappreciated.
OBJECTIVE: The aim of this study was to understand lobar and segmental patterns of emphysema heterogeneity, which may more precisely indicate optimal target sites for LVR procedures.
METHODS: Patterns of emphysema heterogeneity were evaluated in a representative cohort of 150 severe (GOLD stage III/IV) chronic obstructive pulmonary disease (COPD) patients from the COPDGene study. High-resolution computerized tomography analysis software was used to measure tissue destruction throughout the lungs to compute heterogeneity (≥15% difference in tissue destruction) between (inter-) and within (intra-) lobes for each patient. Emphysema tissue destruction was characterized segmentally to define patterns of heterogeneity.
RESULTS: Segmental tissue destruction revealed interlobar heterogeneity in the left lung (57%) and right lung (52%). Intralobar heterogeneity was observed in at least one lobe of all patients. No patient presented true homogeneity at a segmental level. There was true homogeneity across both lungs in 3% of the cohort when defining heterogeneity as ≥30% difference in tissue destruction.
CONCLUSION: Many LVR technologies for treatment of emphysema have focused on interlobar heterogeneity and target an entire lobe per procedure. Our observations suggest that a high proportion of patients with emphysema are affected by interlobar as well as intralobar heterogeneity. These findings prompt the need for a segmental approach to LVR in the majority of patients to treat only the most diseased segments and preserve healthier ones.
© 2015 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26430783      PMCID: PMC4756593          DOI: 10.1159/000439544

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  24 in total

Review 1.  Quantitative computed tomography assessment of lung structure and function in pulmonary emphysema.

Authors:  A Madani; C Keyzer; P A Gevenois
Journal:  Eur Respir J       Date:  2001-10       Impact factor: 16.671

2.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.

Authors:  A Dirksen; J H Dijkman; F Madsen; B Stoel; D C Hutchison; C S Ulrik; L T Skovgaard; A Kok-Jensen; A Rudolphus; N Seersholm; H A Vrooman; J H Reiber; N C Hansen; T Heckscher; K Viskum; J Stolk
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

3.  Lung Volume Reduction in Pulmonary Emphysema from the Radiologist's Perspective.

Authors:  F Doellinger; R H Huebner; J M Kuhnigk; A Poellinger
Journal:  Rofo       Date:  2015-06-10

4.  Computed tomography predictors of response to endobronchial valve lung reduction treatment. Comparison with Chartis.

Authors:  Maren Schuhmann; Philippe Raffy; Youbing Yin; Daniela Gompelmann; Ipek Oguz; Ralf Eberhardt; Derek Hornberg; Claus Peter Heussel; Susan Wood; Felix J F Herth
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

Review 5.  Emphysema: Imaging for Endoscopic Lung Volume Reduction.

Authors:  B Storbeck; T H Schröder; M Oldigs; K F Rabe; C Weber
Journal:  Rofo       Date:  2015-04-21

Review 6.  Endoscopic volume reduction in COPD- a critical review.

Authors:  Daniela Gompelmann; Ralf Eberhardt; Felix Herth
Journal:  Dtsch Arztebl Int       Date:  2014-12-05       Impact factor: 5.594

Review 7.  Segmental approach to lung volume reduction therapy for emphysema patients.

Authors:  Sourish Bandyopadhyay; Erik Henne; Avina Gupta; Robert Barry; Greg Snell; Charlie Strange; Felix J F Herth
Journal:  Respiration       Date:  2014-12-06       Impact factor: 3.580

8.  Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents.

Authors:  P S Bakke; V Baste; R Hanoa; A Gulsvik
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

9.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema.

Authors:  Alfred Fishman; Fernando Martinez; Keith Naunheim; Steven Piantadosi; Robert Wise; Andrew Ries; Gail Weinmann; Douglas E Wood
Journal:  N Engl J Med       Date:  2003-05-20       Impact factor: 91.245

10.  Design of the randomized, controlled sequential staged treatment of emphysema with upper lobe predominance (STEP-UP) study.

Authors:  Arschang Valipour; Felix J F Herth; Ralf Eberhardt; Pallav L Shah; Avina Gupta; Robert Barry; Erik Henne; Sourish Bandyopadhyay; Greg Snell
Journal:  BMC Pulm Med       Date:  2014-12-03       Impact factor: 3.317

View more
  11 in total

Review 1.  Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice.

Authors:  Arschang Valipour
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 2.  Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease.

Authors:  Joseph Em van Agteren; Khin Hnin; Dion Grosser; Kristin V Carson; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

3.  Use of Ventilation-Perfusion Single-Photon Emission Computed Tomography to Select the Target Lobe for Endobronchial Valve Lung Volume Reduction.

Authors:  Vanessa Sze Theen Tee; Phan Nguyen; Hubertus Jersmann; Dion Grosser; Benjamin Crouch; Brett Lorraine; Chong Ghee Chew
Journal:  Respiration       Date:  2021-03-26       Impact factor: 3.580

4.  Lung perfusion and emphysema distribution affect the outcome of endobronchial valve therapy.

Authors:  Christian Thomsen; Dorothea Theilig; Dominik Herzog; Alexander Poellinger; Felix Doellinger; Nils Schreiter; Vera Schreiter; Dirk Schürmann; Bettina Temmesfeld-Wollbrueck; Stefan Hippenstiel; Norbert Suttorp; Ralf-Harto Hubner
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-06-09

5.  Comparison of distinctive models for calculating an interlobar emphysema heterogeneity index in patients prior to endoscopic lung volume reduction.

Authors:  Dorothea Theilig; Felix Doellinger; Alexander Poellinger; Vera Schreiter; Konrad Neumann; Ralf-Harto Hubner
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-06-01

6.  Predictive Modelling of Lung Function using Emphysematous Density Distribution.

Authors:  Kuo-Lung Lor; Cheng-Pei Liu; Yeun-Chung Chang; Chong-Jen Yu; Cheng-Yi Wang; Ming-Jui Chung; Fan-Ya Lin; Chung-Ming Chen
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

7.  Endoscopic lung volume reduction with endobronchial valves in very low D LCO patients: results from the German Registry - Lungenemphysemregister e.V.

Authors:  Pavlina Lenga; Christoph Ruwwe-Glösenkamp; Christian Grah; Joachim Pfannschmidt; Jens Rückert; Stephan Eggeling; Sven Gläser; Bernd Schmidt; Paul Schneider; Sylke Kurz; Gunda Leschber; Andreas Gebhardt; Birgit Becke; Olaf Schega; Jakob Borchardt; Ralf-Harto Hübner
Journal:  ERJ Open Res       Date:  2021-01-25

8.  Bullous Parametric Response Map for Functional Localization of COPD.

Authors:  Kuo-Lung Lor; Yeun-Chung Chang; Chong-Jen Yu; Cheng-Yi Wang; Chung-Ming Chen
Journal:  J Digit Imaging       Date:  2022-01-11       Impact factor: 4.056

9.  Risk factors predict frequent hospitalization in patients with acute exacerbation of COPD.

Authors:  Xia Wei; Zhengquan Ma; Nan Yu; Jingting Ren; Chenwang Jin; Jiuyun Mi; Meijuan Shi; Libin Tian; Yanzhong Gao; Youmin Guo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-27

10.  Efficacy and safety of bronchoscopic lung volume reduction therapy in patients with severe emphysema: a meta-analysis of randomized controlled trials.

Authors:  Yong Wang; Tian-Wen Lai; Feng Xu; Jie-Sen Zhou; Zhou-Yang Li; Xu-Chen Xu; Hai-Pin Chen; Song-Min Ying; Wen Li; Hua-Hao Shen; Zhi-Hua Chen
Journal:  Oncotarget       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.